A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs RT 001 (Primary)
- Indications Friedreich's ataxia
- Focus Registrational; Therapeutic Use
- Sponsors Retrotope
- 01 Nov 2019 Status changed from not yet recruiting to recruiting.
- 23 Sep 2019 Status changed from planning to not yet recruiting.
- 20 Apr 2018 New trial record